Efzofitimod: meta-analysis of COVID-19 studies

All studies Mortality Hospitalization Serious outcomes Recovery RCTs RCT mortality All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−291%

Mortality (1)−291%

Hospitalization (1)−24%

RCTs (1)−291%

Late (1)−291%

00.511.5+

← Efzofitimod
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Efzofitimod COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Walker (DB RCT)−291%3.91 · 0.20–74.70death2/220/10

Late treatment−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.37

All studies−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3700.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Walker (DB RCT)−291%3.91 · 0.20–74.702/220/10

Late treatment−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.37

All studies−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3700.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Walker (DB RCT)−24%1.24 · 0.64–2.42hosp. time12 (n)10 (n)

Late treatment−24%1.24 · 0.64–2.4212 (n)10 (n)24% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.53

All studies−24%1.24 · 0.64–2.4212 (n)10 (n)24% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5300.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Walker (DB RCT)−291%3.91 · 0.20–74.70death2/220/10

Late treatment−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.37

All studies−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3700.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Walker (DB RCT)−11%1.11 · 0.11–10.78no recov.2/181/10

Late treatment−11%1.11 · 0.11–10.782/181/1011% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.93

All studies−11%1.11 · 0.11–10.782/181/1011% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9300.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Walker (DB RCT)−291%3.91 · 0.20–74.70death2/220/10

Late treatment−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.37

All studies−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3700.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Walker (DB RCT)−291%3.91 · 0.20–74.702/220/10

Late treatment−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.37

All studies−291%3.91 · 0.20–74.702/220/10291% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3700.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →

c19early.org

October 2026

Efzofitimod COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Walker (DB RCT)−291%3.91 · 0.20–74.70death2/220/10 Walker (DB RCT)−24%1.24 · 0.64–2.42hosp. time12 (n)10 (n) Walker (DB RCT)−22%1.22 · 0.61–2.44hosp. time12 (n)10 (n) Walker (DB RCT)−56%1.56 · 0.13–17.94hosp. time10 (n)10 (n) Walker (DB RCT)−11%1.11 · 0.11–10.78no recov.2/181/10 Walker (DB RCT)17%0.83 · 0.06–11.70no recov.1/121/10 Walker (DB RCT)−67%1.67 · 0.13–22.01no recov.1/61/10 Walker (DB RCT)−7%1.07 · 0.11–10.04no recov.2/151/8 Walker (DB RCT)20%0.80 · 0.06–10.89no recov.1/101/8 Walker (DB RCT)−60%1.60 · 0.13–20.22no recov.1/51/8

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Efzofitimod
reduces riskEfzofitimod
increases risk →